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Toshimitsu MisAKi， Haruo HisAzuMi， Tadao UcmBAyAsm）
      Tadashi TAyA． and Kyoichi KuRoDA
From癖DopartmehtげUrolO9］，，＆hool of Medicine，1（anazato・a翫ゴび6γ∫め，
           （Director’P糧ズ・κ． Kurodaノ
 The cytocidal effect of 6 anticancer agents on in vitro cultivated KK－47 cells， established from a
human bladder carcinoma， was determined by a colony forming method． Carboquone showed the
most remarkab｝e cytotoxic effects量n tcrms of the assessment of 50 percent Iethal dose in the 2一， and
                                        ナ24－hour exposures of anticancer agents；3．5×10－3 and l．1×10 3μg／ml． A combined exposure of Uro－
kinase（10CTA u．！ml）， and carboquone（2．0×ユ0－3μg／ml）resulted in a significant decrease of cell
growth as compared wlth the single exposure of carboquone， In add｛tionJ 3H－thymidine uptakes of
the cells wcre remarkably reduced by the combination exposure．
  Based on the results obtained in the experimental studies， a combined intravesical instillation
therapy of carboquone and urokinase fbr the prevention of recurrence of bladder carcinoma was per．
fc）rmed in 17 patients． One Qf the玉7 patie且ts showcd．@a recurrence of bladder carcinoma・The
recurrence rate for 14months after operation was 6．3 percent using an actuarial mcthod． No signifi－
cant side effect was observed． The combined ingtillation thcrapy was considcred a potent usefhl

























































 すでに報告したごとく8），colony forming method
を用いて抗癌剤の殺細胞作用を定量的に測定した．す
なわちthio－TEPA， blcomycin， NK－631（bleomycin









    cell suspension 40・一・60 cells／mi
    in Ham’s F12＋ 20ele C．S，
           L
 inoculation roO’一soO ceHs／dish and incubation
 at 37 OC for 24 hrs in air ＋ L5 e！o CO2
     ／ x2 or 24 hr exposunes of no exp6sure of
antlcancer agents anticoncer agents
     x ／     5 times washipg wlth mediurn
           J
     incubation for i2・v l5days
           ，
         colony count
Fig． 1． The assay system of cytotoxicity of

























（1） Plating of 5xlO4 cells／m：
｛2） Carboquone a urokinase exposure tor 2 hrs
6days ｛5） CeH count
Fig． 2． An experimental program of cell

























（2） Carboquone ＆ urokinase exposure for 2 hrs
   （5） Administrotion ot iH－TdR（O．5一）CVml｝ for 6 hrs
7 doys （4） Liquid scintillation counter
Fig．3． An experimental progra皿of cellular





4g， POPOP （1， 4－bis［2一（5’一phenyloxazolyl）］一benzine，
和光純薬工業，東京）0．lgを加えたシンチレーター
液10mlを添加して，液体シンチレーションカウンタ




















Table 1． Combined intravesical instillation therapy with carboquone and urokinase．

































































































































































































































Table 3． Growth inhibitory effects of the use
     of carboquone and／or urokinase on




Urokinase （IO CTA units／m 1 ）






Table 4． Combined effects of carboquone and
     urokinase on 3H－thymidine uptake









55，044．5 ± 1，44 1．5
Table 5．
三崎・ほか：Carboquone urokinase併用注入療法
Recurrence rate following combined intravesical instillation therapy with
carboquone and urokinase （actuarial method）．
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討し，carboquone， neocarzinostatin， actinomycin D，

























































Cytoslne arabinoside 十 urokinose
thio－TEPA 十 urokinase
carboquone 十 urokinose
o 3 6 9 12 15 18 21 24 （mos）
          Postoperative observation period
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訂正；Table 3の＋はすべて±に訂正します．
